Anteros enters the market powered by BioMotiv and Bristol-Myers Squibb

The biotech company focuses on developing new drugs for fibrotic and other inflammatory diseases

Anteros Pharmaceuticals is a new biotechnology company and is the first company launched from the partnership between Bristol-Myers Squibb (BMS) and BioMotiv announced last September.

Anteros will be focused on developing a new class of drugs for fibrotic and other inflammatory diseases.

The intellectual property behind Anteros was first developed by Yale University and in-licensed by BMS and subsequently assigned to Anteros.

Under the terms of the partnership, BMS will contribute the IP, data, and reagents for a series of small molecules against an undisclosed mechanism. BioMotiv, through the formation of Anteros Pharmaceuticals, and working in close partnership with Yale, will be solely responsible for research and development.

Once Anteros nominates a pre-clinical candidate, BMS has the option to acquire the company from BioMotiv under pre-agreed terms.

“Anteros Pharmaceuticals is the first of several companies that BioMotiv and Bristol-Myers Squibb intend to form under the Strategic Partnership Agreement,” said Satish Jindal, Ph.D., BioMotiv’s CEO.

“Our broader mission is to translate novel discoveries into breakthrough therapies for patients in need, forming companies such as Anteros to achieve this goal,” Jindal added.

Rupert Vessey, President of Research and Early Development at BMS, said the pharma giant is committed to partnering with innovative collaborators like BioMotiv, in such agreements that expand the reach and capabilities in early-stage research.

“These types of partnerships also enable us to progress the transformational research being performed at leading academic institutions such as Yale and effectively translate those discoveries into new therapies for patients,” he added.

Companies